A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS)
Publication
, Conference
Attia, S; Riedel, RF; Robinson, SI; Conry, RM; Sankhala, KK; Seon, BK; Alvarez, D; Adams, BJ; Theuer, CP; Maki, RG
Published in: JOURNAL OF CLINICAL ONCOLOGY
May 20, 2015
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2015
Volume
33
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Attia, S., Riedel, R. F., Robinson, S. I., Conry, R. M., Sankhala, K. K., Seon, B. K., … Maki, R. G. (2015). A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 33). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
Attia, Steven, Richard F. Riedel, Steven Ian Robinson, Robert Martin Conry, Kamalesh Kumar Sankhala, Ben K. Seon, Delia Alvarez, Bonne J. Adams, Charles P. Theuer, and Robert G. Maki. “A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 33. AMER SOC CLINICAL ONCOLOGY, 2015.
Attia S, Riedel RF, Robinson SI, Conry RM, Sankhala KK, Seon BK, et al. A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS). In: JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.
Attia, Steven, et al. “A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS).” JOURNAL OF CLINICAL ONCOLOGY, vol. 33, no. 15, AMER SOC CLINICAL ONCOLOGY, 2015.
Attia S, Riedel RF, Robinson SI, Conry RM, Sankhala KK, Seon BK, Alvarez D, Adams BJ, Theuer CP, Maki RG. A phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) in combination with pazopanib in patients with advanced soft tissue sarcoma (STS). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2015.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2015
Volume
33
Issue
15
Location
Chicago, IL
Publisher
AMER SOC CLINICAL ONCOLOGY
Conference Name
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences